Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...
Understand RA from early to advanced stages. Explore symptoms, treatments, and lifestyle tips to manage rheumatoid arthritis ...
The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 years, more untreated controls died than those treated with IV edaravone. Treatment with ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study ...
It is highly desirable to predict the progression of Alzheimer's disease (AD) of patients [e.g., to predict conversion of mild cognitive impairment (MCI) to AD], especially longitudinal prediction of ...
Novo's blockbuster diabetes drug Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ...
Periodontal disease is classically characterized by progressive destruction of the soft and hard tissues of the periodontal complex, mediated by an interplay between dysbiotic microbial communities ...
Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...
Spinal cord stimulation restores neural function, targets key feature of progressive neurodegenerative disease. ScienceDaily . Retrieved February 7, 2025 from www.sciencedaily.com / releases ...
Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and ...
Background Development of autonomic failure is associated with more rapid disease course and shorter survival in patients with Parkinson’s disease and multiple system atrophy. However, autonomic ...
During menopause, estrogen levels drop, so there’s reason to think menopause may affect MS disease progression. “We know that hormonal changes during puberty can trigger autoimmune diseases ...